Core Insights - Hemotune, a Swiss medical technology company founded in 2017, focuses on developing magnetic adsorption beads for targeted blood purification, particularly for sepsis patients [2][6] - Sepsis, a severe infection form, affects nearly 50 million people annually, leading to approximately 11 million deaths, highlighting the urgent need for effective treatment methods [4] - Hemotune's proprietary magnetic adsorption beads are designed to selectively remove large biomolecules from blood, offering a more efficient and multi-targeted approach to blood purification compared to traditional methods [6] Company Overview - Hemotune was co-founded by Lukas Langenegger and Carlos Mora, both affiliated with ETH Zurich, with Langenegger serving as CEO and Mora as CTO [2] - The company has developed a complete blood purification system that includes magnetic adsorption beads, a dialysis-like treatment device, and disposable components for blood contact [6] Technology and Innovation - The magnetic adsorption beads are composed of non-toxic magnetic nanoparticles, allowing for high specificity in targeting various blood compounds [6] - The system enables continuous supply of fresh adsorption beads, preventing saturation issues and allowing for simultaneous removal of multiple disease-related compounds [6] Financial and Strategic Developments - In March 2023, Hemotune partnered with AstraZeneca for a joint feasibility project [7] - The company completed a Series B1 funding round in April 2022, raising 7.25 million Swiss francs, followed by a Series B2 round in March 2024, raising 14 million Swiss francs to advance clinical trials and commercialization [7] Recognition and Impact - Hemotune was listed among the TOP100 Swiss Startups in 2022, a prestigious recognition highlighting innovative and market-potential companies in Switzerland [9]